Best Value Stocks this February 2026

Amazon is poised for significant growth, with Wolfe Research predicting 2026 as a pivotal year, driven by an acceleration in AWS growth to the mid-20% range and the recent acquisition of a $581 million Pentagon cloud contract. Currently, analysts maintain a strong outlook with a median price target of $300.00, highlighting positive ratings from firms like TD Cowen and Wells Fargo. Given its recent 1-year return of 3.93% and a robust 5-year return of 51.38%, Amazon represents an attractive option for investors looking to capitalize on its expanding market presence.

Merck stands out as a defensive healthcare leader with a solid cash flow and an impressive product pipeline. With a dividend yield of 3.27% and a 1-year return of 10.17%, it presents an attractive option for income-focused investors seeking stability. Analysts are optimistic, giving it a median 12-month price target of $120 and a strong A- rating, indicating confidence in its future performance.

Analysts estimate that Merck could reach approximately $111 per share by 2027, indicating a potential upside of 28% from current levels, or about 12% annualized returns.

Expedia stands out as a top-ranked travel technology stock, boasting a Zacks Rank of #1 (Strong Buy). With a remarkable 1-year return of 57.73% and a 5-year return of 116.49%, it appeals to investors seeking substantial growth. Analysts have a positive outlook, with a consensus Buy rating and a median 12-month price target of $270.00, indicating strong potential for further gains.

As of January 20, 2026, 25 analysts rate Expedia (EXPE) as a Buy, indicating positive sentiment towards the stock.

Our Discounted Cash Flow analysis indicates that Expedia Group is undervalued by 59.5%.

Taiwan Semiconductor Manufacturing Company (TSMC) represents a compelling investment opportunity, with its stock currently trading below fair value estimates despite being a critical player in the global chip manufacturing landscape. With a strong 1-year return of 75.93% and a 5-year return of 177.92%, TSMC's potential for growth remains robust, particularly with a recent 20% dividend increase adding further appeal to investors. Analysts give it a B+ rating and set a median price target of $405.00, indicating confidence in its future performance.

TSM is expected to maintain strong growth through 2026, making it a solid investment, especially with the recent 20% dividend increase.

S&P Global stands out as a quiet compounder, showcasing strong pricing power and dependable recurring revenue streams. With a solid 1-year return of 1.14% and an impressive 5-year return of 71.95%, the company offers a dividend yield of 0.73%. Analysts maintain a positive outlook, with a median 12-month price target of $629.50, indicating a potential stock price growth of 16.30% moving forward.

SPGI has strong growth potential, with an estimated stock price growth of 16.30%, making it an attractive option for long-term investors.

S&P Global's earnings per share (EPS) grew at a compounded annual growth rate of 20% over the last two years, indicating improved profitability.

The consensus rating from 17 Wall Street analysts is 'Buy,' with 16 analysts recommending a buy and 1 a strong buy for SPGI.

DoorDash is poised for growth, with projected improvements in gross order value and an expected EBITDA increase of 3% by FY2027, driven by automation and enhanced unit economics. Ideal for investors looking for robust long-term potential, the company is anticipated to achieve mid-teens organic gross order value growth in the coming years. Analysts currently maintain a median price target of $280, with a range between $224 and $350, reflecting a B- rating overall, indicating a cautious yet optimistic outlook on DoorDash's performance.

Yes, DoorDash is expected to see strong growth, with projected mid-teens organic gross order value growth and an adjusted EBITDA growth rate exceeding 30% annually.

Analysts estimate that DoorDash could reach approximately $468 per share by 2027, indicating a potential 73% gain from current levels.

Micron Technology is a promising cyclical semiconductor stock benefiting from improving fundamentals and exposure to AI, making it an attractive option for growth-focused investors. With a remarkable 1-year return of 350.27% and a 5-year return of 446.33%, the company is currently trading near the upper range of its 52-week prices. Analysts maintain a positive outlook, with a median 12-month price target of $350.00 and ratings from firms like Mizuho and Stifel indicating a strong buy sentiment.

MU stock is currently trading near its 52-week high and above its 200-day moving average, with a recent increase of $2.07, or 0.52%.

AbbVie employs an income-plus-growth strategy, supported by a diversified pharmaceutical pipeline that includes promising immunology drugs like Skyrizi and Rinvoq. With a solid dividend yield of 3.10% and impressive returns of 26.58% over the past year and 117.84% over five years, the company is well-positioned for long-term growth. Analysts maintain a median price target of $258, reflecting a cautious sentiment with recent ratings ranging from neutral to overweight.

ABBV's new immunology drugs, Skyrizi and Rinvoq, support its potential for long-term growth, and it currently holds a #3 (Hold) rating on the Zacks Rank.

AbbVie (ABBV) is currently trading near the midpoint of its 52-week range, above its 200-day moving average, but has seen a recent decline of 1.11%, or $2.40.

Netflix stands out as a global media platform, noted for its ability to generate consistent free cash flow. Despite a challenging year with a return of -11.95%, the stock has delivered an impressive 63.54% return over the last five years. Analysts maintain a median 12-month price target of $113.50, reflecting confidence in its long-term potential amid mixed ratings, including a “Buy” from Argus Research and a “Hold” from Pivotal Research.

A $100 investment in Netflix stock 10 years ago would be worth approximately $821 today, reflecting a 721% increase.

Netflix shares (NFLX) closed at $88.00, down $0.05 or 0.06% from the previous market close.

Chewy stands out as a promising small/mid-cap investment, with expectations of reaching a 10% EBITDA margin by the end of 2028, driven by increasing advertising revenue and automation. Despite a challenging current performance, reflected in a one-year return of -19.70% and a staggering five-year drop of -69.90%, analysts maintain a cautiously optimistic outlook, with a median 12-month price target of $49.00. Notably, firms like Morgan Stanley and Goldman Sachs have reiterated their Overweight and Buy ratings, suggesting potential for recovery as revenue is projected to grow by 8% in fiscal 2027.

Analysts project an 8% revenue increase for Chewy in fiscal 2027, suggesting a potential recovery in the stock by 2026 as investor awareness grows.

With an expected increase in operating margin from 0.9% to 4.6% by fiscal 2030, Chewy could see annual earnings growth of 18%, despite current economic pressures.

Meta Platforms is targeting a robust 20% growth in ad revenue by 2026, driven by the monetization of Threads and WhatsApp alongside new features. Despite facing challenges like rising capital expenditures and the uncertain impact of generative AI, analysts maintain a positive outlook with a median price target of $830.00 and a B+ rating, indicating confidence in its strategic direction.

Meta's stock is underperforming due to rising capital expenditures, uncertainty regarding the benefits of generative AI, and concerns about its margins and valuation.

Analysts believe Meta could see significant growth by 2026, as current forecasts are conservative, assuming slower growth and lower profits due to AI investments.